IDH1 and leukemia: Even though promising results are being reported for IDH1 inhibitors in early clinical trials in leukemia [43, 44], our results indicate that monotherapy using mutant IDH1 inhibition may not be sufficient to use as a treatment option for patients with inoperable or metastatic central chondrosarcomas harboring this mutation.